Imu asx

Imugene Limited. Imugene Limited, a clinical stage immuno-oncology company, develops a imu asx of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. About the company.

January 19, Bronwyn Allen. Investors are excited over some further news released by the company today. January 17, James Mickleboro. November 28, James Mickleboro. November 10, James Mickleboro. The healthcare stock is roaring higher again on Friday. But what's getting investors excited?

Imu asx

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its product pipeline includes an off-the-shelf allogeneic cell therapy CAR T drug Azer-Cel azercabtagene zapreleucel which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia pox virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Financial Times Close. Search the FT Search. Show more World link World. Show more US link US. Show more Companies link Companies. Show more Tech link Tech. Show more Markets link Markets. Show more Opinion link Opinion.

Add to Your Portfolio New portfolio. All rights reserved.

Market data is provided and copyrighted by Thomson Reuters and Morningstar. Click for restrictions. All rights reserved. ASX shareholders. Our Board.

Key events shows relevant news articles on days with large price movements. Race Oncology Ltd. RAC Immutep Ltd. IMM 8. Pilbara Minerals Ltd. PLS 0.

Imu asx

Financial Times Close. Search the FT Search. Show more World link World. Show more US link US. Show more Companies link Companies. Show more Tech link Tech. Show more Markets link Markets. Show more Opinion link Opinion. Show more Personal Finance link Personal Finance.

Korean bbq all u can eat near me

Add to Your Portfolio New portfolio. Clarity Pharmaceuticals Ltd. He has made contributions to the development and approval of ten oncology drugs and has orchestrated development programs for numerous drugs. How do Imugene's earnings and revenue compare to its market cap? Day Change. Leadership Team. Mr Hopper has over 20 years experience in the management and funding of biotechnology and healthcare public companies as chairman, chief executive officer and director in Australia and the United States. The company specialises in clinical-stage immuno-oncology therapies. Shareholders have been diluted in the past year. Financial Times Close. He is a mentor for lifescience entrepreneurs and start-up teams in the area of innovative lifescience and healthcare information technology companies. Issuer Services.

Market data is provided and copyrighted by Thomson Reuters and Morningstar.

DLT as a Service. Price target decreased by 9. Corporate Governance. How do Imugene's earnings and revenue compare to its market cap? Connectivity services. Dividend Yield 0. Show more Personal Finance link Personal Finance. Investor Presentations. Use our equities screener to discover other potential opportunities. A verification email has been sent.